Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Long-Term Oncological Outcomes after Endoscopic Submucosal Dissection of Superficial Esophageal Cancer.

Created on 16 Oct 2026

Authors

Tae Jun Kim, Yang Won Min, Young Eun Oh, Tae-Se Kim, Hyuk Lee, Byung-Hoon Min, Jun Haeng Lee

Published in

Gut and liver. Oct 15, 2026. Epub Oct 15, 2026.

Abstract

Long-term data on the cumulative risk of lymph node metastasis (LNM), particularly after non-curative resection, remain limited. This study aimed to analyze long-term outcomes and clarify the risk of LNM.
This retrospective study included 892 patients (951 cases) who underwent endoscopic submucosal dissection for superficial esophageal cancer. Extraesophageal recurrence-free survival (RFS) and overall survival (OS) were analyzed based on pathological strata, including depth of invasion and lymphovascular invasion (LVI).
In the observation group, the 5-year RFS and OS rates were 95.6% (95% confidence interval [CI], 92.8% to 97.3%) and 91.4% (95% CI, 88.2% to 93.8%) for mucosal/LVI-negative, and 92.7% (95% CI, 73.7% to 98.1%) and 84.9% (95% CI, 72.9% to 91.9%) for submucosal/LVI-negative subgroups, respectively. Conversely, the submucosal/LVI-positive group showed lower 5-year RFS (51.9%; 95% CI, 16.4% to 78.8%) and OS rates (61.4%; 95% CI, 29.9% to 82.2%) (p<0.001). Additional surgery was associated with higher 5-year RFS and OS rates of 76.1% (95% CI, 59.8% to 86.4%) and 87.5% (95% CI, 71.9% to 94.7%), respectively, in the submucosal/LVI-positive subgroup. The LNM risk in mucosal cases was primarily synchronous. However, the submucosal/LVI-positive group exhibited a cumulative increase in LNM detection, with the rate increasing from 28.3% at the time of surgery to 50.0% during follow-up.
Esophageal endoscopic submucosal dissection achieves excellent long-term outcomes for curative resection. Non-curative cases, particularly those with submucosal invasion and LVI, exhibit an evolving LNM risk over time. These high-risk patients may be considered for additional treatment when medically suitable, alongside meticulous, long-term oncological surveillance.

PMID:
42880864
Bibliographic data and abstract were imported from PubMed on 16 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 15
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement